Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Down 21.5% in December

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 116,200 shares, a drop of 21.5% from the December 15th total of 148,000 shares. Based on an average daily trading volume, of 208,200 shares, the days-to-cover ratio is currently 0.6 days. Approximately 2.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

VVOS has been the topic of a number of research analyst reports. Alliance Global Partners dropped their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 19th. Ascendiant Capital Markets restated a “buy” rating and issued a $6.60 price target on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.

Vivos Therapeutics Stock Up 16.2 %

Vivos Therapeutics stock opened at $5.95 on Friday. The company’s 50-day moving average price is $4.05 and its two-hundred day moving average price is $3.11. The stock has a market cap of $28.80 million, a P/E ratio of -1.05 and a beta of 7.51. Vivos Therapeutics has a twelve month low of $1.91 and a twelve month high of $9.14.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.